Hsiang-Lin Tsai
Overview
Explore the profile of Hsiang-Lin Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
1544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chuang J, Tsai H, Chen P, Huang C, Su W, Chang T, et al.
Kaohsiung J Med Sci
. 2025 Mar;
:e70008.
PMID: 40078099
Neoadjuvant chemoradiotherapy (NACRT) is the standard treatment for patients with locally advanced rectal cancer (LARC). Tumor regression grade (TRG) is an essential prognostic factor in determining treatment efficacy. However, the...
2.
Chen Y, Chang T, Su W, Yeh Y, Chen P, Huang P, et al.
Int J Colorectal Dis
. 2024 Oct;
39(1):171.
PMID: 39453531
Background: Metastatic colorectal cancer (mCRC) poses a clinical challenge and requires a combination of systemic therapy and conversion surgery. Although first-line chemotherapy and targeted therapy are considered the standard treatments...
3.
Chuang J, Tsai H, Su W, Chen P, Huang C, Chang T, et al.
Oncol Res
. 2024 Oct;
32(11):1723-1732.
PMID: 39449806
The pTNM staging system is widely recognized as the most effective prognostic indicator for cancer. The latest update of this staging system introduced a new pathological staging system (ypTNM) for...
4.
Yin T, Chen Y, Su W, Chang T, Chen P, Li C, et al.
Surg Endosc
. 2024 Oct;
38(12):7621-7626.
PMID: 39433589
Background: Intracorporeal anastomosis offers notable advantages over extracorporeal techniques, including reduced tissue manipulation leading to faster recovery and potentially lower risks of surgical site infections and complications. However, it also...
5.
Chen C, Chang S, Chang Y, Lin B, Chen H, Hsieh Y, et al.
Am J Cancer Res
. 2024 Jan;
13(12):6333-6345.
PMID: 38187069
This multicenter study aimed to explore the survival benefit of metastasectomy by first-line cetuximab-based chemotherapy in real-world patients with wild-type metastatic colorectal cancer (mCRC). The primary endpoints were overall survival...
6.
Tsai H, Huang C, Chen Y, Su W, Chang T, Chen P, et al.
Medicina (Kaunas)
. 2023 Dec;
59(12).
PMID: 38138211
: Approximately 5-10% of all patients with metastatic colorectal cancer (mCRC) harbor a mutation. These patients exhibit distinct metastatic patterns, poor prognosis, and heterogenous survival outcomes. The findings from the...
7.
Chen Y, Huang C, Li C, Chang T, Su W, Chen P, et al.
World J Surg Oncol
. 2023 Dec;
21(1):378.
PMID: 38041083
Background: Systemic therapy is the standard treatment for unresectable colorectal cancer with liver metastasis (CRCLM). Transarterial chemoembolization with drug-eluting beads (DEB-TACE) is considered an effective treatment option for CRCLM. Few...
8.
Tsai H, Yeh Y, Chen P, Chang Y, Chen Y, Su W, et al.
Integr Cancer Ther
. 2023 Oct;
22:15347354231187153.
PMID: 37822243
Patients with cancer use low-molecular-weight fucoidan (LMF) as a supplement to therapy. However, most studies of LMF are or conducted using animals. Concurrent chemoradiotherapy (CCRT) is the gold standard for...
9.
Tsai H, Shi H, Chen Y, Huang C, Su W, Chang T, et al.
Am J Cancer Res
. 2023 Oct;
13(9):4039-4056.
PMID: 37818063
This study investigated the cost-effectiveness and quality of life (QoL) within 1 year of receiving mFOLOFX6 with or without a targeted drug (bevacizumab or ramucirumab) as second-line treatment among patients...
10.
Chen Y, Tsai H, Liang P, Wang J
Kaohsiung J Med Sci
. 2023 Aug;
39(10):1054-1055.
PMID: 37530671
No abstract available.